Government
In a filing this week, the government said that tens of thousands of patients received “unreliable blood tests,” which deprived them of money and placed their health at risk.
Candidates pointed out ways they would use the power of the federal government to lower the cost of medications in the United States.
As is often the case at the beginning and end of the year, a number of companies announced layoffs. Other news is related to lawsuits and an overall positive story about cancer death rates. Here’s a look.
With a new year underway, the U.S. Food and Drug Administration is doing some house-cleaning of sorts.
Clinicians and scientists from National Heart Centre Singapore, Duke-NUS Medical School’s Cardiovascular & Metabolic Disorders Programme (CVMD) and SingHealth Duke-NUS Academic Medical Centre (AMC)s’ discovery of a key driver of fibrosis and inflammation in human diseases is now moving rapidly toward the clinic.
The site location is in Swiftwater, Pennsylvania.
Merck’s checkpoint inhibitor Keytruda (pembrolizumab) continues moving toward the projections of becoming the world’s best-selling drug.
Study showed that two metabolic enzymes in the proline metabolic pathway are potential targets to inhibit cancer cell growth, and offers new hope for effective liver cancer treatments
A Chinese scientist living abroad who has been accused of accepting stolen intellectual property to benefit a pharma startup in China has been extradited to the United States.
This is a list of new molecular entities and new therapeutic biological products approved by the agency’s Center for Biologics Evaluation and Research in 2019.
PRESS RELEASES